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A hybridoma cell  line producing a  monoclonal anti- 
body directed to N-acetylneuraminosyl-c2+6-galac- 
tosyl residue has been established. The antibody is 
IgG2b and reacts only with  lacto-series gangliosides as 
well as with glycoproteins having an N-acetylneura- 
minosyl-c~2~6-galactosyl residue, but does not react 
with gangliosides or glycoproteins having  an  N-ace- 
tylneuraminosyl-c2+3- or -a2-4-galactosyl residue. 
The antibody is useful for detecting the specific car- 
bohydrate chain having  this terminal structure by im- 
munostaining of glycolipids separated on thin layer 
chromatography or glycoproteins separated on gel 
electrophoresis after blotting on nitrocellulose sheet. 
A remarkable accumulation of a few gangliosides hav- 
ing  this terminal structure has been detected by this 
monoclonal antibody in some human cancer. 
Monoclonal antibodies directed to defined carbohydrate 
structures have been isolated and have proven to be useful 
probes in  determination of the carbohydrate profile at  the cell 
surface and expedient  reagents in determination of carbohy- 
drate  structures (1-9). This approach  has been conveniently 
applied for analysis of antigen profiles, in combination with 
the immunostaining of glycolipids separated on thin layer 
chromatography (10) and glycoproteins separated  on gel elec- 
trophoresis followed by blotting  on nitrocellulose sheet (11). 
Recently, a new type of lacto-series ganglioside having a 
sialosyl-a2+6-galactosyl terminus was isolated and charac- 
terized from human erythrocytes (12) and  human meconium 
(13). Two gangliosides having this  terminal structure, sialosyl- 
lacto-neotetraosylceramide and sialosyl-lacto-norhexaosyl- 
ceramide, were isolated and characterized as minor compo- 
nents of human erythrocytes  (12). The former ganglioside was 
found to be the major component of human meconium (13). 
Glycoproteins having the carbohydrate  chain with the termi- 
nal sialosyl-a2+6-galactosyl residue have been found to be 
widely distributed (see for a review Ref. 14), particuIarly in 
blood plasma glycoproteins (e.g. Refs. 15-17). The present 
paper describes establishment of a hybridoma secreting the 
IgG2b antibody, which reacts specifically with the sialosyl- 
a2-6-galactosyl structure  in gangliosides as well as in gly- 
coproteins, and  the application of this antibody to detect this 
structure at  nanogram  order. 
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RESULTS 
Production of the Hybridoma-Fusion of the  NS/1 myeloma 
with spleen cells of mice immunized against sialosyl-a2+6- 
lacto-neotetraosylceramide yielded about  3% positive clones 
by the first assay after  the fusion. Two clones, IB2 and IB9, 
were isolated which appeared to have the same reactivity, 
specifically to sialosyl-a2-6-lacto-neotetraosylceramide, but 
showed no reactivity to sialosyl-a2~3-lacto-neotetraosylcer- 
amide. They were derived from the same well (lIIC8) of the 
original fusion plate and were derivatives of the same clone. 
Both hybridomas, IB2 and IB9, can be propagated in BALB/ 
c mice as ascites form, producing high titer antibody. Anti- 
bodies from these hybridomas were identified as IgG2b class, 
and were successfully propagated as ascites form in “pris- 
tane”-treated BALB/c mice. 
Specificity of the Antibody-Antibodies produced by both 
hybridomas, IB2 and IB9, showed identical specificity, and 
the supernatant fluid of the hybridomas showed the same 
specificity as ascites. The results described in this paper are 
those with the IB9 antibody. The reactivity of the antibody 
with various gangliosides and glycoproteins is shown in  Figs. 
1 and 2, respectively. It is clear that only lacto-series ganglio- 
sides containing the sialosyl-a2+6-galactosyl residue showed 
a specific reactivity. All other gangliosides failed to react with 
by the authors. Miniprint is easily read with the aid of a standard 
magnifying glass. Full size photocopies are available from the  Journal 
of Biological Chemistry, 9650 Rockville Pike,  Bethesda, MD 20814. 
Request Document No. 83M-1087, cite the authors, and include a 
check or money order for $1.00 per set of photocopies. Full size 
photocopies are also included in  the microfilm edition of the  Journal 






























Dilution of Ascites 
*t 
0 
Dilution of Antigen Glycolipid 
FIG. 1. Reactivity of various gangliosides with the mono- 
clonal antibody IB9 determined by solid phase radioimmu- 
noassay. A shows the reactivity of various gangliosides using 100 
ng/well with lecithin and cholesterol (see text). The activity was 
determined with  various dilutions of  hybridoma  ascites. 0, sialosyl- 
a24-lacto-neotetraosylceramide; 0, sialosyl-~u2-+6-lacto-norhexao- 
sylceramide; A, sialosyl-a2+3-lacto-neotetraosylceramide; 0, G M ~  
ganglioside; 0, GMl ganglioside. E shows the reactivity of various 
gangliosides with different concentrations by solid phase radioim- 
munoassay.  The original concentration (100 ng/well) was diluted  and 
coated on the plate with cholesterol  and  lecithin  and  determined  with 
1 0 0 ~  diluted ascites of IB9 hybridoma. 0, sialosyl-~2-.6-lacto-lzeo- 
tetraosylceramide; D, lacto-neotetraosylceramide; V, GMz ganglioside; 
B, GM, ganglioside; A, cholesterol  and  lecithin  without ganglioside. 
the  antibodies  present in the  supernatant or in  ascites. Human 
plasma  fibronectin was shown to have an  N-acetylneurami- 
nosyl-cu2-+6-galactosyl residue (17), and gave a positive re- 
action with this  antibody (Fig. 2 A ) .  In  contrast,  the majority 
of the sialosyl residue in bovine plasma  fibronectin is linked 
through  the cu2-+4Gal structure  and only  a minority is linked 
through the n2+6Gal structure (25). This reflects  a low 
reactivity of bovine fibronectin with this  antibody (Fig. 2B). 
Bovine  submaxillary mucin, which has  the NeuAcaB-, 
6GalNAc structure (14), showed  a strong reactivity with  this 
antibody (Fig. 2C). However, human  erythrocyte glycophorin 
(27), which has a  major  oligosaccharide chain  with  the  struc- 
ture NeuAc~2--*3Gal/3l"t3(NeuAccu2+6)GalNAc (as), did 
not show any appreciable reaction with this antibody (Fig. 
20) ,  although glycophorin has one asparagine-linked com- 
plex-type oliogasaccharide containing the NeuAca24Gal 
residue as a minor  component  (29).  The reactivity of human 
plasma fibronectin and bovine submaxillary mucin to this 
antibody was abolished by treatment with Vibrio cholerae 
sialidase  (see Fig. 2,  A and C). The weak reactivity of bovine 
plasma  fibronectin  to  this  antibody was slightly reduced by 
sialidase treatment. These results clearly indicate that the 
antibody recognizes NeuAcn2+6Gal and NeuAca2+ 
Dilution of Anttbody (ascites) 
FIG. 2. Reactivity of glycoproteins in solid phase radioim- 
munoassay with the monoclonal antibody IB9. The glycoprotein 
solutions were incubated  in 96-well Dynatech  plates  overnight  and 
analyzed  according to  the procedure as previously  described (1). The 
concentration of glycoprotein for primary  coating on Dynatech  plates 
was as follows: 0.1 mg/ml of human  plasma  fibronectin, bovine  plasma 
fibronectin, and bovine submaxillary mucin; 0.25 mg/ml of human 
erythrocyte glycophorin.  Bovine serum  albumin (0.5 mg/ml) was used 
as a  background coat. A ,  human  plasma  fibronectin; B, bovine plasma 
fibronectin; C, bovine submaxillary mucin; D, human erythrocyte 
glycophorin. 0, 0, A, and V, intact molecules; 0, B, A, and 7, 
glycoproteins treated with V. cholerae sialidase; - - -, background 
value with bovine serum albumin. 
6GalNAc at  the  terminus.  The  latter  structure  at  the  internal 
residue, such as found  in glycophorin (28), was not reactive. 
Other  types of sialosyl linkages in various  glycoproteins, i.e. 
a2-3Ga1, a24Ga1,  and  cu24GlcNAc, were not reactive to 
this  antibody. 
Determination of Gangliosides and Glycoprotein Profiles 
Having NeuAca24Gal Residue-Ganglio-series and lacto- 
series gangliosides having the  NeuAca24Gal residue were 
separated on high performance thin layer chromatography 
and  immunostained  as shown  in Fig. 3. None of the ganglio- 
series gangliosides were stained (Fig. 3, Lane 5 ) .  A doublet 
corresponding  to sialosyl-cu2+6-lacto-neotetraosylceramide 
(band h)  and a band corresponding to a  sialosyl-c~2+6-lacto- 
norhexaosylceramide (band  i) were stained  (Lane 6). In  addi- 
tion, a slower migrating band was detected which has not 
been characterized  (Lane 6). This  component could be con- 
tamination  present  in  the reference sample of  G9' ganglioside 
(30). A ganglioside fraction isolated  from  two  cases of human 
cancer (Fig. 3, Lanes 3 and 4 )  and their immunostaining 
pattern  (Lanes 7 and 8) are also shown. GH3 was the major 
component  in  both cases (Lanes 3 and 4 ) ;  however, a glycolipid 
showing  a  doublet  corresponding to sialosyl-cu2-4-lacto-neo- 
tetraosylceramide (a doublet in Lane 3 corresponding to band 
h  in Lane  2) was found  as  the second major component in one 
The abbreviations used are: G9, Fuccul-+2Gal/314GlcNAcP1+ 
6[NeuAcn2~3Gal/3l"t4GlcNAc~l~3]Gal~l-.4GlcNAc~l--*3Gal~1 
+4Glcpl+lCer (other assignments for ganglio-series gangliosides 
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FIG. 3 (left). Immunostaining pattern of various gangliosides with monoclonal antibody IBQ. The 
various gangliosides were separated  on high performance  thin layer chromotography  plate (J. T. Baker Chemical 
Co., Phillipsburg, NJ)  in a solvent mixture of choloroform/methanol/water (60:35:8, v/v/v). Lanes 1-4 were 
revealed by orcinol/sulfuric acid reaction. Lanes 5-8 are an autoradiogram of the chromatogram developed 
simultaneously  and  immunostained with  monoclonal antibody IB9. Lane I, a mixture of standard  brain gangliosides. 
Bands a-fare, respectively, G M ~ ,   G M ~ ,  G ,,  Gola GDlb, and GTlb gangliosides. Designation of these  brain gangliosides 
is according to Svennerholm (33). Lane 2 is a mixture of standard  lacto-series gangliosides  isolated and previously 
characterized (12). A doublet band g represents sialosyl-a2+3-lacto-neotetraosylceramide (the  two  bands  represent 
different  ceramides); a doublet band h represents sialosyl-a2+6-lacto-neotetraosylceramide (the two bands  repre- 
sent different ceramides); band i, sialosyl-a2+6 lacto-norhexaosylceramide; band j ,  G9 ganglioside (a branched 
fucoganglioside with ceramide decasaccharide structure (30). Lane 3, ganglioside fraction of hepatocarcinoma 
(diagnosed as adenocarcinoma). Lane 4, ganglioside fraction of primary  lung  carcinoma  metastatic  to liver. 
FIG. 4 (right). Immunostaining of fibronectins  separated on  gel electrophoresis  followed  by  blotting 
on nitrocellulose sheet. Lane 1, human plasma fibronectin; Lane 2, thermolysin digest of human plasma 
fibronectin (31); Lane 3, desialylated human  plasma  fibronectin by hydrolysis in 1% acetic acid. Left margin shows 
identification of the  fragments. FN, intact  fibronectin. 
case (Lane 3) .  This  component was immunostained intensely 
by the  antibody  (Lane 7). In  addition, slower migrating bands, 
including the one  corresponding to sialosyl-a2+6-lacto-nor- 
hexaosylceramide and another with slower mobility, were 
detected as being stained by the  antibody  (Lane 7). This  type 
of large accumulation of gangliosides having the NeuAca2- 
6Gal residue was not observed in the other case of human 
cancer  (lung  cancer  metastatic  to liver)  shown in Lanes 4 and 
8. The major gangliosides chemically detectable  in  this case 
were GM:< and sialosyl-a2+3-lacto-neotetraosylceramide 
(Lune 4 ) ,  which were not immunostained by this antibody 
(Lune 8). Only a small quantity of sialosyl-a24-lacto-neo- 
tetraosylceramide was detected, which was weakly immuno- 
stained by this  antibody  (Lane 8). 
As an example of glycoproteins  having the  NeuAca24Gal 
residue, human plasma fibronectin, its thermolysin digest, 
and desialylated products were separated  on gel electropho- 
resis and  immunostained  after  blotting on  nitrocellulose 
sheet. An intense  band was immunostained for intact fibro- 
nectin (Fig. 4, Lane I), and a doublet with M, = 140,000- 
150,000, 105,000,44,000, and 23,000 was immunostained after 
thermolysin digestion (Lune 2) (31). An intense fibronectin 
stain was completely  lost after  the sialosyl residue of fibro- 
nectin was eliminated  (Lane 3) .  
DISCUSSION 
Profiles of cell surface  carbohydrates have been probed and 
defined by lectins  (32). This  approach  has been strengthened 
and  partially replaced by monoclonal antibodies directed to 
defined carbohydrate  structures.  Another potentially  impor- 
tant use of anti-carbohydrate monoclonal antibodies is their 
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munostaining procedure  recently developed on thin layer 
chromatography  (10)  and  blotting of electrophoretic gels on 
nitrocellulose sheets (11) is highly sensitive  and  requires only 
nanogram  quantities of material.  Immunostaining of complex 
carbohydrates by multiple  monoclonals  in combination  with 
enzymatic hydrolysis will be potentially useful to elucidate 
the  structure of nanogram  quantities of carbohydrates, if the 
necessary number of well defined monclonal antibodies  are 
available. Efforts  to gain increasing  numbers of well defined 
monoclonal anti-carbohydrate  antibodies  are  essential  to 
reach such a goal. 
The  antibody described  in this  paper defines the  terminal 
residue NeuAca24Gal  in glycolipids and glycoproteins and 
the  NeuAca24GalNAc residue in glycoproteins. The  anti- 
body does not  react  with  the  internal sialosyla2+6GalNAc 
residue  (28) linked  to polypeptides since glycophorin,  which 
contains  this  structure, was not reactive. 
The  structure NeuAca2+6Gal (or GalNAc) is known to be 
widely distributed  in a variety of glycoproteins as  the  terminus 
of the  short  0-linked oligosaccharide in  mucin-type glycopro- 
teins, i.e. NeuAca2+6GalNAcal+O-Ser (Thr), and as the 
terminus in the side chain of a complex type asparagine- 
linked  structure, i .e .  NeuAca2-+6Gal~l+4GlcNAc~l+ 
2Manal-R (see  for  a review Ref. 14),  although  such a 
structure  has been confirmed only relatively recently based 
on methylation  analysis (15-17, 25). Determination of such 
structures  in glycoproteins requires  isolation of oligosaccha- 
rides or glycopeptides after degradation, and methylation 
analysis before and  after desialylation, and  needs  at  least 0- 
200 pg of glycopeptides. If glycoproteins contain 3-5% car- 
bohydrates  (like  fibronectin), a minimum  quantity  to  obtain 
the  information  on sialosyl  linkage would be at  least 2-3 mg 
of glycoprotein. The  results shown in Figs. 3 and 4  required 
only 100 ng of the glycoprotein. Since neither a ganlioside 
having N-glycolylneuraminosyl-a24-galactosyl residue nor 
a  glycoprotein exclusively containing  this  structure  have been 
isolated, we have had  no  chance  to  test  the  reactivity of the 
IB9 antibody  to  this  structure. 
On  the  other  hand,  the NeuAca2+6Gal structure  is rarely 
found  in sialosyl glycolipids (gangliosides), and  the  structure 
constitutes  the  terminus of the  type 2 N-acetyllactosaminyl 
chain, i.e. NeuAc~24Gal~l+4GlcNAc~1+3Gal~1+R. 
Gangliosides with  this  structure have  been  isolated and  char- 
acterized only recently (12, 13). Two types of gangliosides 
have been isolated and characterized from human erythro- 
cytes (12); one is sialosyl-a2+6-lacto-neotetraosylceramide 
(G4)  and  the  other  is sialosyl-a24-lacto-norhexaosylceram- 
ide (G7).  The  quantity of these gangliosides  in human  eryth- 
rocytes  was  very low (G4 and G7 comprised 1.9 and 1.4% of 
the total gangliosides of human erythrocytes, respectively) 
(12). Normal colonic  mucosal tissue  and  normal iver contain 
similar quantities of these gangliosides. Interestingly, the 
quantity of gangliosides having this  terminal  structure was 
found  to be much higher in some human  cancers,  and sialosyl- 
a2-6-lacto-neotetraosylceramide is a major ganglioside of 
some human cancers. The ganglioside composition of only 
two cases of human cancer are presented in this paper, as 
shown in Fig. 3. One  accumulated sialosyl-a2+6 gangliosides 
and  the  other did not. However, we have  observed many  other 
cases, and  the  results of these  studies will be published  else- 
where. Since sialosyl-~2-+6-lacto-neotetraosylceramide is the 
major ganglioside in meconium (13), but represents only a 
minor  component  in various normal  tissues,  the  remarkable 
accumulation of this ganglioside in  human cancer may reflect 
an oncofetal  expression of this ganglioside. The  antibody is 
useful in  determining  the profile of gangliosides and sialosyl 
structures  in  tissues  and cells. 
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